Immunohistochemistry (IHC) plays a vital role in the characterization of breast cancer, utilizing biomarkers such as hormone receptors (HR), human epidermal growth factor receptor 2 (HER2), Ki-67, and lymph node metastasis (LNM) to identify subtypes, predict prognosis, and assess treatment responsiveness (4). This evidence concerns the gene ERBB2 and breast carcinoma.